Shattuck Labs, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Shattuck Labs, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $10.00K, a 99.20% decline year-over-year.
- Shattuck Labs, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $1.26M.
- Shattuck Labs, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $31.00K.
- Shattuck Labs, Inc. stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $214.00K.
- Shattuck Labs, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $229.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-06-30 | $10.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.26M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $31.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $229.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $214.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |